Alimera Sciences Inc ALIM
We take great care to ensure that the data presented and summarized in this overview for ALIMERA SCIENCES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ALIM
Top Purchases
Top Sells
About ALIM
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Insider Transactions at ALIM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 16
2024
|
Philip Ashman President of Int'l Operations |
SELL
Sale (or disposition) back to the issuer
|
Direct |
118,274
-100.0%
|
-
|
|
Sep 16
2024
|
Jason M. Werner Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
225,000
-50.0%
|
-
|
|
Sep 16
2024
|
Peter J. Pizzo Iii Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
500
-100.0%
|
-
|
|
Sep 16
2024
|
Richard S Eiswirth Jr President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
324,018
-100.0%
|
-
|
|
Sep 16
2024
|
David Holland Chief Marketing Officer & SVP |
SELL
Sale (or disposition) back to the issuer
|
Direct |
187,756
-100.0%
|
-
|
|
Sep 16
2024
|
John Snisarenko Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,000
-100.0%
|
-
|
|
Sep 16
2024
|
Caligan Partners LP > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
16,835,154
-100.0%
|
-
|
|
Sep 16
2024
|
Adam Morgan Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
13,608,533
-100.0%
|
-
|
|
Mar 26
2024
|
Philip Ashman President of Int'l Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
12,103
-9.28%
|
$36,309
$3.83 P/Share
|
|
Jan 10
2024
|
Philip Ashman President of Int'l Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
2,938
-2.2%
|
$8,814
$3.86 P/Share
|
|
Oct 02
2023
|
Jason M. Werner Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
225,000
+50.0%
|
-
|
|
Oct 02
2023
|
Richard S Eiswirth Jr President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
400,000
+35.63%
|
-
|
|
Sep 14
2023
|
Caligan Partners LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
579,000
+3.32%
|
$1,737,000
$3.39 P/Share
|
|
Sep 14
2023
|
Caligan Partners LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
579,000
-3.44%
|
$1,737,000
$3.39 P/Share
|
|
Aug 15
2023
|
Adam Morgan Director |
BUY
Conversion of derivative security
|
Indirect |
11,948,879
+38.79%
|
$11,948,879
$1.83 P/Share
|
|
Aug 15
2023
|
Caligan Partners LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
13,431,616
+44.38%
|
$13,431,616
$1.7 P/Share
|
|
Aug 15
2023
|
Caligan Partners LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,924,761
+46.22%
|
$5,849,522
$2.1 P/Share
|
|
May 17
2023
|
Adam Morgan Director |
BUY
Open market or private purchase
|
Indirect |
1,401,901
+45.79%
|
$1,401,901
$1.7 P/Share
|
|
Mar 26
2023
|
Philip Ashman President of Int'l Operations |
BUY
Grant, award, or other acquisition
|
Direct |
103,000
+43.59%
|
-
|
|
Mar 26
2023
|
David Holland Chief Marketing Officer & SVP |
BUY
Grant, award, or other acquisition
|
Direct |
68,000
+38.44%
|
-
|
Last 12 Months Summary
| Other acquisition or disposition | 16.8M shares |
|---|---|
| Sale (or disposition) back to the issuer | 14.5M shares |
| Payment of exercise price or tax liability | 15K shares |